

BioNexus Gene Lab invests \$250K for AI-based healthcare innovation in Malaysia

19 April 2024 | News

Announces plans to invest RM 1.2 million in Ascension Innovation to advance digital health innovation



BioNexus Gene Lab Corporation (BGLC), a global leader in genomic diagnostics and healthcare technology, has announced a strategic investment by its wholly owned subsidiary, MRNA Scientific Sdn Bhd, in Ascension Innovation Sdn Bhd (AISB), a privately held Malaysian company.

MRNA Scientific's investment of RM 1.2 million (approx. \$250k) will occur in two tranches. The company has made an initial payment of approx. RM 100k, to be followed by a final payment of RM 1.1million, subject to a formal agreement.

The investment in AISB signifies a strategic move to accelerate healthcare innovation. The investment, funded internally, is expected to constitute an indicative equity of approximately 10% of the ordinary shares in AISB upon completion.

The infusion of capital will further AISB's development and accelerate its artificial intelligence (AI) rollout, including AI Assistance in the Clinic and on-App. The AI features include the integration of predictive and generative AI note taking/analysis and diagnosis aids via Large Language Model (LLM), voice transcription, and natural language assistance for service selection and bookings.

aiCMS, AISB's flagship platform, will enhance early disease detection and personalized health recommendations in clinic and on-app, with the integration of in-app predictive health and wellness recommendations, medical translation services, and AI medical image analysis.

This strategic investment will allow BGLC's Blood-based Genomic Screening (BGS) liquid biopsies and other diagnostic services to be better marketed and accessible to a wider range of customers and healthcare providers, through integration into AISB's aiCMS and the aiCARE app, enabling direct booking via healthcare providers and patients.